Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

TNXPBullishCorporate Developmentsnews

High materiality7/10

Tonix Launches HORIZON Phase 2 MDD Trial for TNX-102 SL

Jun 29, 2026, 7:33 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Milestone-driven Phase 2 enrollment news can re-rate expectations for TNX-102 SL’s MDD potential; upside hinges on positive MADRS signals and eventual readouts, with Tonix’s fibromyalgia franchise providing a partial cushion.

AI summary

What happened, with direct paths to the underlying reporting

Tonix announced the first patient enrollment in HORIZON, a Phase 2 trial of TNX-102 SL 5.6 mg as a first-line MDD therapy. The 6-week MADRS-focused study expects about 360 patients across ~30 sites. If positive, the program could broaden TNX-102 SL’s use beyond fibromyalgia, leveraging sleep-improvement signals.

First patient enrolled in HORIZON Phase 2 MDD trial for TNX-102 SL 5.6 mg.
HORIZON targets MADRS change at Week 6 in ~360 patients across ~30 US sites.
TNX-102 SL previously studied for sleep improvement and fibromyalgia; TONMYA launched in 2025.
Patent protections extend U.S. market exclusivity to 2034; method-of-use patents possible to 2044.
Tonix aims to expand TNX-102 SL into MDD and other sleep-related indications.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Tonix Launches HORIZON Phase 2 MDD Trial for TNX-102 SL

Tonix gains from second GPO coverage expansion for TONMYA, 52M lives

Tonix Expands TONMYA Patient Access, Stock Rallies Over 5%

Tonix Pharmaceuticals Reports Positive Early Adoption of TONMYA and Solid Financials

US FDA approves Tonix Pharma's drug to manage pain related to chronic condition